Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: A case series in China
Lancet 2025 Doi:10.1016/S0140-6736(25)01671-X Epub ahead of print
Gao et al. report that allogeneic CAR NK-cell therapy is a potent option for treatment of autoimmune diseases and may address limitations of current autologous CAR T-cell therapy, including manufacturing scale and time, access, safety, and cost. Authors evaluated the safety, tolerability, and efficacy of allogeneic CD19 CAR NK-cell therapy in patients with relapsed or refractory SLE.
CAR NK -cell therapy showed encouraging preliminary efficacy in patients with relapsed or refractory SLE who had been systematically pretreated. Treatment allowed discontinuation of high-dose GCs and sustained withdrawal of conventional immunosuppressants, achieving resolution of treatment-emergent toxicities. CAR NK -cell therapy demonstrated slower kinetics in achieving dsDNA antibody seroconversion and did not induce DORIS remission in all patients, underscoring a distinct efficacy profile.
Keywords:
